YOUR MONTHLY DIABETES DOWNLOAD
|
For Type 1s, Type 2s, Loved Ones & Healthcare Professionals | MAY 2026
|
|
|
|
Misdiagnosis, missed treatment opportunities, and mystery lows…don't let them happen to you!
This month, we're highlighting the benefits of earlier GLP-1 use, the reasons why LADA is so misdiagnosed, and a little known condition called reactive hypoglycemia. Let's clear a few things up! 
|
|
|
|
YOUR MONTHLY DIABETES DOWNLOAD
|
For Type 1s, Type 2s, Loved Ones & Healthcare Professionals | MAY 2026
|
|
|
|
Misdiagnosis, missed treatment opportunities, and mystery lows…don't let them happen to you!
This month, we're highlighting the benefits of earlier GLP-1 use, the reasons why LADA is so misdiagnosed, and a little known condition called reactive hypoglycemia. Let's clear a few things up
|
|
|
|
|
|
Type 2 Diabetes | Medications
If you could go back in time and protect your future heart, kidneys, and eyesight…you would, right? Starting the right treatment earlier in type 2 diabetes might do just that, and more! Here’s why our long-standing type 2 diabetes treatment strategy needs an update.
|
|
|
|
Type 2 Diabetes | Medications
|
|
|
If you could go back in time and protect your future heart, kidneys, and eyesight…you would, right? Starting the right treatment earlier in type 2 diabetes might do just that, and more! Here’s why our long-standing type 2 diabetes treatment strategy needs an update.
|
|
|
|
|
|
Type 1 Diabetes | LADA
It’s not a secret that a significant number of adults with type 1 diabetes are being misdiagnosed every year. But why is it happening? In our latest article, we explore the most commonly missed diagnosis in diabetes and share the tests that can provide the answers you need.
|
|
|
|
|
|
It’s not a secret that a significant number of adults with type 1 diabetes are being misdiagnosed every year. But why is it happening? In our latest article, we explore the most commonly missed diagnosis in diabetes and share the tests that can provide the answers you need.
|
|
|
|
|
|
Type 2 Diabetes | Reactive Hypoglycemia
If you aren’t on diabetes medications and your blood sugar suddenly spikes and then crashes after eating something sweet or high in carbs, you may have reactive hypoglycemia. Here’s what’s going on (and what to do about it).
|
|
|
|
Type 2 Diabetes | Reactive Hypoglycemia
|
|
|
If you aren’t on diabetes medications and your blood sugar suddenly spikes and then crashes after eating something sweet or high in carbs, you may have reactive hypoglycemia. Here’s what’s going on (and what to do about it).
|
|
|
|
|
|
Big News for Families Navigating Early T1D!
|
Type 1 Diabetes | Medications
The FDA has expanded approval of Tzield to treat kids as young as one year old with stage 2 type 1 diabetes. This is a big deal because it means we can now delay the onset of stage 3 T1D in children who often experience a faster and more aggressive disease course (loss of beta cells).
Tzield is the first disease-modifying therapy that targets the underlying autoimmune process of T1D, helping slow the attack on insulin-producing beta cells. For families, this delay can mean more time without insulin, fewer daily management challenges during toddler years, and time to become educated about managing the condition and avoiding ketoacidosis. The approval was fast-tracked based on data from the PETITE-T1D study, and ongoing research is exploring the use of Tzield in older children and adults after type 1 diabetes (stage 3) is diagnosed.
|
|
|
|
Big News for Families Navigating Early T1D!
|
Type 1 Diabetes | Medications
|
|
|
The FDA has expanded approval of Tzield to treat kids as young as one year old with stage 2 type 1 diabetes. This is a big deal because it means we can now delay the onset of stage 3 T1D in children who often experience a faster and more aggressive disease course (loss of beta cells).
Tzield is the first disease-modifying therapy that targets the underlying autoimmune process of T1D, helping slow the attack on insulin-producing beta cells. For families, this delay can mean more time without insulin, fewer daily management challenges during toddler years, and time to become educated about managing the condition and avoiding ketoacidosis. The approval was fast-tracked based on data from the PETITE-T1D study, and ongoing research is exploring the use of Tzield in older children and adults after type 1 diabetes (stage 3) is diagnosed.
|
|
|
|
|
|
First AID System Is FDA Approved for Use During Pregnancy with T1D
|
Diabetes News | Technology | Pregnancy
The FDA recently cleared Tandem’s Control-IQ+ as the first and only automated insulin delivery (AID) system approved for use during pregnancy. Pregnancy comes with tighter blood sugar targets, which can make diabetes management especially challenging. In the CIRCUIT trial, women using CIQ+ spent about 3 more hours a day in their pregnancy target range (63–140 mg/dL) compared to those using their standard therapy. CIQ+ powers both the t:slim X2 and Mobi insulin pumps, offering two options to help women stay in range more often during a time when glucose management matters more than ever.
|
|
|
|
First AID System Is FDA Approved for Use During Pregnancy with T1D
|
Diabetes News | Technology | Pregnancy
|
|
|
The FDA recently cleared Tandem’s Control-IQ+ as the first and only automated insulin delivery (AID) system approved for use during pregnancy. Pregnancy comes with tighter blood sugar targets, which can make diabetes management especially challenging. In the CIRCUIT trial, women using CIQ+ spent about 3 more hours a day in their pregnancy target range (63–140 mg/dL) compared to those using their standard therapy. CIQ+ powers both the t:slim X2 and Mobi insulin pumps, offering two options to help women stay in range more often during a time when glucose management matters more than ever.
|
|
|
|
|
|
A New Ozempic Pill Is Here!
|
Diabetes News | Type 2 Diabetes | Medications
The FDA recently approved an oral form of semaglutide called Ozempic pill, which launched in the U.S. on May 4th. An earlier oral version of semaglutide called Rybelsus has been available since 2019, but the makers of Ozempic developed the new tablet version to better align with the Ozempic name. Ozempic pill is indicated for adults with type 2 diabetes, and is available in 1.5 mg, 4 mg, and 9 mg doses. Rybelsus will remain on the market in its current doses of 3 mg, 7 mg, and 14 mg.
|
|
|
|
A New Ozempic Pill Is Here!
|
Diabetes News | Type 2 Diabetes | Medications
|
|
|
The FDA recently approved an oral form of semaglutide called Ozempic pill, which launched in the U.S. on May 4th. An earlier oral version of semaglutide called Rybelsus has been available since 2019, but the makers of Ozempic developed the new tablet version to better align with the Ozempic name. Ozempic pill is indicated for adults with type 2 diabetes, and is available in 1.5 mg, 4 mg, and 9 mg doses. Rybelsus will remain on the market in its current doses of 3 mg, 7 mg, and 14 mg.
|
|
|
|
|
|
We Want to Hear From YOU!
|
Is there anything we can do to make this newsletter more helpful and supportive for your diabetes journey? Please take a minute to complete our short survey, and let us know what you love, what you’d like more of, and how we can improve. Your voice shapes what we create next! Thank you for being part of our community!
|
|
|
|
We Want to Hear From YOU!
|
|
|
Is there anything we can do to make this newsletter more helpful and supportive for your diabetes journey? Please take a minute to complete our short survey, and let us know what you love, what you’d like more of, and how we can improve. Your voice shapes what we create next! Thank you for being part of our community!
|
|
|
|
TCOYD Community Quote of the Month
|
"Excellent tips, especially the advice to be kind to oneself regarding highs and lows and the acknowledgement of how difficult it is to live with diabetes. Having endocrinologists with type 1 discuss the disease makes all the difference, as you have intimate knowledge of the daily struggles!"
|
TCOYD® is a 501(c)(3) nonprofit educational organization. Our vision is for all people with diabetes and their loved ones to have full access to proper education and therapy, in order to allow for the prevention, early detection, and aggressive management of diabetes and the complications of diabetes.
|
|
|
|
Please consider helping TCOYD® improve the lives of those living with diabetes by supporting our virtual educational programs. To learn more, click below.
|
|
|
|
|
HUGE SHOUTOUT TO OUR SUPPORTING COMPANIES! |
|
|
|
Taking Control Of Your Diabetes® is a 501(c)(3) Nonprofit Charitable Educational Organization, Edutaining the Diabetes Community Since 1995.
|
|
|
|
|
